Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 420,674
  • Shares Outstanding, K 88,007
  • Annual Sales, $ 36,630 K
  • Annual Income, $ -39,960 K
  • 60-Month Beta 2.27
  • Price/Sales 10.79
  • Price/Cash Flow N/A
  • Price/Book 3.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.28
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.53
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.19 +49.84%
on 08/27/20
4.78 unch
on 09/18/20
+1.38 (+40.59%)
since 08/18/20
3-Month
2.53 +88.93%
on 07/01/20
4.78 unch
on 09/18/20
+1.99 (+71.33%)
since 06/18/20
52-Week
1.04 +359.62%
on 03/16/20
4.78 unch
on 09/18/20
+2.97 (+164.09%)
since 09/18/19

Most Recent Stories

More News
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering

Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement...

CKPT : 3.40 (-3.13%)
FBIO : 4.78 (+6.46%)
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

-- 51.4% objective response rate and 13.5% complete response rate in half the planned pivotal cohort

CKPT : 3.40 (-3.13%)
FBIO : 4.78 (+6.46%)
Thinking about buying stock in Myomo Inc, Parsley Energy, Fortress Biotech, AVEO Pharmaceuticals, or Nio Inc?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYO, PE, FBIO, AVEO, and NIO.

AVEO : 6.25 (+2.63%)
PE : 9.93 (-2.84%)
FBIO : 4.78 (+6.46%)
MYO : 4.99 (-6.73%)
NIO : 19.41 (+0.57%)
Thinking about buying stock in Delta Air Lines, Scientific Games, GameStop, Vertex Pharmaceuticals, or Fortress Biotech?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, SGMS, GME, VRTX, and FBIO.

DAL : 32.84 (-3.30%)
FBIO : 4.78 (+6.46%)
GME : 9.47 (+2.93%)
SGMS : 32.96 (+6.84%)
Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis

- Caelum Biosciences, a company founded by Fortress, is collaborating with Alexion Pharmaceuticals on the studies

FBIO : 4.78 (+6.46%)
Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

--- Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78% at 37 months) and durable organ response -

ALXN : 113.72 (-0.36%)
FBIO : 4.78 (+6.46%)
Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences

Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and...

FBIO : 4.78 (+6.46%)
Mustang Bio to Participate in Three September 2020 Virtual Investor Conferences

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 3.88 (+7.78%)
FBIO : 4.78 (+6.46%)
Avenue Therapeutics Announces Publication of a Review of IV Tramadol

Avenue Therapeutics, Inc. (NASDAQ: ATXI) ("Avenue"), a company focused on the development of intravenous ("IV") tramadol for the U.S. market, today announced that a publication entitled "IV tramadol: A...

ATXI : 11.50 (+3.05%)
FBIO : 4.78 (+6.46%)
Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic...

MBIO : 3.88 (+7.78%)
FBIO : 4.78 (+6.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade FBIO with:

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

2nd Resistance Point 4.99
1st Resistance Point 4.89
Last Price 4.78
1st Support Level 4.57
2nd Support Level 4.35

See More

52-Week High 4.78
Last Price 4.78
Fibonacci 61.8% 3.35
Fibonacci 50% 2.91
Fibonacci 38.2% 2.47
52-Week Low 1.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar